Advertisement

Keywords

Insulin Resistance Metabolic Syndrome Glycemic Index United Kingdom Prospective Diabetes Study Heart Protection Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 2.
    Turner RC, Millins H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823–828.PubMedGoogle Scholar
  2. 3.
    Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. JAMA 1982;248:1465–1477.Google Scholar
  3. 4.
    Grundy S, Becker D, Clarke L, et al. National Cholesterol Education Program (Adult Treatment Panel 111). Detection, education, and treatment of high blood cholesterol in adults. Circulation 2002;106: 3143–3420.CrossRefGoogle Scholar
  4. 5.
    Wallace AM, McMohan AD, Pickard CJ, et al. Plasma leptin and the risk of cardiovascular disease in West of Scotland Coronary Prevention Study. Circulation 2001;104:3052–3056.PubMedGoogle Scholar
  5. 6.
    Ridker PM, Wilson WF, Grundy SM. Should CRP be added to metabolic syndrome and to the assessment of global cardiovascular risk? Circulation 2004;109:2818–2825.PubMedGoogle Scholar
  6. 7.
    Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease. Circulation 1999;100:1134–1146.PubMedGoogle Scholar
  7. 8.
    Borch Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, et al. Urinary albumen excretion: an independent predictor of ischemic heart disease. Arterioscler Throm Vasc Biol 1999;19:1992–1997.Google Scholar
  8. 9.
    Cohn JM, Quyyumi AA, Hollenberg NK, et al. Surrogate markers for CVD. Circulation 2004;109(suppl):1V-37–46.Google Scholar
  9. 10.
    Klausen, Borch-Johnsen K, Feldt-Rasusson B, et al. Very low levels of microalbuminuria are associated with increased risk of CHD and death independently of renal function, hypertension and diabetes.Google Scholar
  10. 11.
    Kshirsagar AV, Joy MS, Hogan SL, et al. Effects of ACE inhibitors in diabetic and non-diabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000;35: 695–707.PubMedGoogle Scholar
  11. 12.
    Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: result of HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–259.Google Scholar
  12. 13.
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effects of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456–1462.PubMedGoogle Scholar
  13. 14.
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131): 854–865.Google Scholar
  14. 15.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.PubMedGoogle Scholar
  15. 16.
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcome in patients with type 2 diabetes and nephropathy (RENNAL study). N Engl J Med 2001;345:861–869.PubMedCrossRefGoogle Scholar
  16. 17.
    Davi G, Ciabottoni G, Consoli A, et al. In vivo formation of 8-isoprostaglandin F2a and platelet activation in diabetes mellitus: effects of improved metabolic control. Circulation 1999;99:224–229.PubMedGoogle Scholar
  17. 18.
    Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979;59:8–13.PubMedGoogle Scholar
  18. 19.
    Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Educational Program goal vs “usual care” in secondary CHD prevention. The Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study. Curr Med Res Opin 2002; 18;220–228.PubMedGoogle Scholar
  19. 20.
    Athyros VG, Papageorgious AA, Symeonidis AN, et al. Early benefit from structured care with atorvastatin in patients with coronary heart disease. Angiology 2003;54:679–960.PubMedCrossRefGoogle Scholar
  20. 21.
    Thomason MJ, Colhoun HM, Livingstone SJ, et al, the CARDS Investigators. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Lancet 2004; 21:685–696.Google Scholar
  21. 22.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrazil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Interventio n Trial Study Group. N Engl J Med 1999; 341:410–418.PubMedCrossRefGoogle Scholar
  22. 23.
    Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20, 536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–12.Google Scholar
  23. 24.
    Obesity in Scotland. Integrating prevention with weight management. A National Clinical Guideline Guideline 55. Scottish Intercollegiate Guidelines Network (SIGN) Edinburgh, 2000.Google Scholar
  24. 26.
    Khan ME, St. Peter JV, Xue J. Prospective randomized comparison trial of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708–711.PubMedGoogle Scholar
  25. 27.
    American Diabetes Association. Consensus Development Conference on Insulin Resistance. Diabetes Care 1998;21:310–314Google Scholar
  26. 28.
    Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmaceutical treatment of insulin resistance in high risk Hispanic women. Diabetes 2002;51:2796–2803.PubMedGoogle Scholar
  27. 29.
    Chiasson JL, Gomis R, Hanefield M, et al. The STOP-NIDDM trial. Acarbose for the prevention of type 2 diabetes. Lancet 2002; 359:2072–2077.PubMedCrossRefGoogle Scholar
  28. 30.
    Knower WC, Barrett-Conner E, Flower SE, et al. Diabetic Prevention Program. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.Google Scholar

Copyright information

© Springer-Verlag London Limited 2005

Personalised recommendations